I have been sucessfully enrolled into a new phase 1 clinical trial which has an identifier of CCS-1477-01. Here are a few links.
https://clinicaltrials.gov/ct2/show/study/NCT03568656
and https://www.cellcentric.com/clinical/
The trial will look at the safety of a new experimental medication CCS1477 and see what effects it has on me and my prostate cancer. The growth of prostate cancer is highly dependant on hormone signals and the function of the androgen receptor (AR) in particular. AR converts even very low levels of hormone (testosterone) into a signal for cells to divide more rapidly. CCS1477 reduces the levels of AR in prostate cancer cells and may therefore slow the growth of the tumour.
I will be in the initial phase, called Dose Escalation which will find out the highest safe dose that can be given without causing too many side effects. The dosing frequency will also be assessed.
Once the highest safe dose has been established the study will progress to treat several other groups of participents.
There will be basically three arms to this trial.
Mono CCS-1477
CCS-1477 given with abiratone
CCS-1477 given with enzalutimide.
I will be on the mono arm. It is going to be taken in capsule form, the amount and frequency to be determined, although a cycle will be 28 days. CT and bone scans to be performed every eight weeks.
As it is at the very early stages, side effects are unknown, although nausea and fatigue are anticipated.
It is anticipated that about 120 people will be recruited for the study overall, from up to 20 hospitals, mainly in the USA but two hospitals in the UK.
If successful, they think it could help about 80,000 prostate cancer sufferers every year.
Thats it for now, I think. Baseline tests and scans straight after Easter then all systems go!
As before, good or bad I will let you know my experiences.
Best regards